Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 233 participants.
Also called NCT02023879
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 233 participants
- Sponsor
- Registry
-
NCT02023879 -
2013-002659-14
-
- Other papers using this trial's data
- Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Canada, Denmark, Netherlands, New Zealand, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02023879. Randomized; triple masking; primary purpose treatment. Start 2013-12-16 (registry gives no type); primary completion 2014-10-27 (actual). Results posted on 2017-03-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Placebo (for Alirocumab)
- Intervention (Drug)
- Non-statin LMT
- Intervention (Other)
- Diet Alone
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct02023879- Content hash
ad946523d875fb7ac6e0f878a61df5ae3fa514ac1eb3a823c842e6c33fc88f2f